EyePoint, Inc. - Common Stock NASDAQ
1 recomendações avaliadas · 1 canais · rastreado desde 17 ago 2026
Últimos 12 meses · 1 comprando · 0 vendendo
Bloomberg Television
Compra
Recs.
1
Retorno
+0,0%
Ver recs.
THE MAIN THING HERE WAS CANCER CUT THE RATING ON THE COMPANY FROM NEUTRAL TO OVERWEIGHT SAYING THE TRIAL MESS WAS A SCENARIO SHOWING WE HAVE NOT EVEN CONTEMPLATED IT IN OUR BOLD BEAR BASE CASE SCENARIO ANALYSIS IN OUR RECENT INITIATION.
